Abstract
The erbB2 gene, which encodes a transmembrane growth factor receptor, is overoxpressed in approximately 30% of breast cancers. Overexpressing this gene makes breast cancers resistant to certain chemotherapeutic agents. In this article, we review what is known about ErbB2-mediated chemoresistance and the controversies surrounding it. We also examine the anti-apoptotic function of erbB2 as one of the molecular mechanisms of ErbB2-mediated Taxol resistance and describe several emerging strategies for overcoming intrinsic ErbB2-mediated chemoresistance. Finally, we discuss future avenues for studies of chemosensitivity in ErbB2-overexpressing breast cancers thai may lead to the development of effective biology-based treatment strategies. (C) 2000 John Wiley and Sons, Inc.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 873-680 |
| Number of pages | 194 |
| Journal | BioEssays |
| Volume | 22 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2000 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology